Abstract:During normal aging, there is a decline in all physiological functions in the organism. One of the most affected organs is the brain, where neurons lose their proper synaptic function leading to cognitive impairment. Aging is one of the main risk factors for the development of neurodegenerative diseases, such as Alzheimer's disease. One of the main responsible factors for synaptic dysfunction in aging and neurodegenerative diseases is the accumulation of abnormal proteins forming aggregates. The most studied brain aggregates are the senile plaques, formed by Aβ peptide; however, the aggregates formed by phosphorylated tau protein have gained relevance in the last years by their toxicity. It is reported that neurons undergo severe mitochondrial dysfunction with age, with a decrease in adenosine 5'-triphosphate production, loss of the mitochondrial membrane potential, redox imbalance, impaired mitophagy, and loss of calcium buffer capacity. Interestingly, abnormal tau protein interacts with several mitochondrial proteins, suggesting that it could induce mitochondrial dysfunction. Nevertheless, whether tau-mediated mitochondrial dysfunction occurs indirectly or directly is still unknown. A recent study of our laboratory shows that phosphorylated tau at Ser396/404 (known as PHF-1), an epitope commonly related to pathology, accumulates inside mitochondria during normal aging. This accumulation occurs preferentially in synaptic mitochondria, which suggests that it may contribute to the synaptic failure and cognitive impairment seen in aged individuals. Here, we review the main tau modifications promoting mitochondrial dysfunction, and the possible mechanism involved. Also, we discuss the evidence that supports the possibility that phosphorylated tau accumulation in synaptic mitochondria promotes synaptic and cognitive impairment in aging. Finally, we show evidence and argue about the presence of phosphorylated tau PHF-1 inside mitochondria in Alzheimer's disease, which could be considered as an early event in the neurodegenerative process. Thus, phosphorylated tau PHF-1 inside the mitochondria could be considered such a potential therapeutic target to prevent or attenuate age-related cognitive impairment.

Tau protein modulates an epigenetic mechanism of cellular senescence in human SH-SY5Y neuroblastoma cells

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Tau affects P53 function and cell fate during the DNA damage response

Tau Protein Antagonizes Cell Apoptosis Through Akt Pathway

Tau Modulates mRNA Transcription, Alternative Polyadenylation Profiles of hnRNPs, Chromatin Remodeling and Spliceosome Complexes

P3‐309: Overexpression of Hyperphosphorylated Tau Antagonizes Aβ‐potentiated Apoptosis with Preservation of Mitochondrial Elements

Astrocyte senescence and SASP in neurodegeneration: tau joins the loop

Profiling senescent cells in human brains reveals neurons with CDKN2D/p19 and tau neuropathology

Aging-associated REGγ proteasome decline predisposes to tauopathy

Protein homeostasis gene dysregulation in pretangle-bearing nucleus basalis neurons during the progression of Alzheimer's disease.

Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease

The Mechanistic Link Between Tau-Driven Proteotoxic Stress and Cellular Senescence in Alzheimer's Disease

Retromer deficiency in Tauopathy models enhances the truncation and toxicity of Tau

The putative contribution of cellular senescence to driving tauopathies

HNRNPA2B1 Mediates the Association of Oligomeric Tau with N 6-Methyladenosine and Neurodegeneration

Aggregation promoting sequences rather than phosphorylation are essential for Tau-mediated toxicity in

Effects of P301L-TAU on post-translational modifications of microtubules in human iPSC-derived cortical neurons and TAU transgenic mice

An HDAC6-dependent Surveillance Mechanism Suppresses Tau-Mediated Neurodegeneration and Cognitive Decline

Phosphorylated tau as a toxic agent in synaptic mitochondria: implications in aging and Alzheimer’s disease

Human iPSC-Derived Neuronal Model of Tau-A152T Frontotemporal Dementia Reveals Tau-Mediated Mechanisms of Neuronal Vulnerability.

Tau depletion in human neurons mitigates Aβ-driven toxicity